Prognostic and Demographic Characteristics of Acute Myelogenous Leukemia Patients: a FiveYear Study in Mashhad, Iran
Allahyari، Abolghasem نويسنده Hematology Oncology Department, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, IR Iran , , Jalalian، Nazanin نويسنده Students Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran Jalalian, Nazanin , Faroughi، Foad نويسنده Students Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. , , Sadeghi، Masoud نويسنده Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran Sadeghi, Masoud
Background: Acute myeloid leukemia (AML) is a disease in elderly patients, with a mean age of diagnosis of 70 years. We have analyzed the clinicopathology features and experimental variables in AML patients in Eastern Iran and the correlation between survival and FAB subgroups of AML.
Materials and Methods: During 2009 to 2014 in a retrospective study, 98 patients with AML referred to the Clinic of Hematology. More of patients had just chemotherapy regimen of “7+3” and none of the patients had radiotherapy. Also, one-third patients had bone marrow transplantation. The mean follow-up was 40 months and at this time, there were 58 deaths.
Results: The mean age of the patients at diagnosis was 40.6±15.4 years (range, 17-77 years) that 40 patients (40.4%) were male. AML-M5 and M3 were the most subgroups in patients with 29.5% and 26.1%, respectively. Twenty patients (20.4%) had lymphadenopathy. Weakness and lethargy were the most complaints. 5-year survival rate was 39.6% and mean survival was 27.3 months. Prevalence of females was more in AML-M5 and M3 compared to other subgroups.
Conclusions: The mean age in Iran and probably Middle East are lower than a lot of countries and also the percentage of females was more in our study compared with a lot of previous studies. OS in our patients is higher than other studies that should be notice to chemotherapy regimen, radiotherapy and bone marrow transplantation in patients in future studies. Prevalence of AML-M5 in our study is higher than other studies.